Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer.

Zucker S, Lysik RM, DiMassimo BI, Zarrabi HM, Moll UM, Grimson R, Tickle SP, Docherty AJ.

Cancer. 1995 Aug 15;76(4):700-8.

PMID:
8625169
2.

Elevated plasma stromelysin levels in arthritis.

Zucker S, Lysik RM, Zarrabi MH, Greenwald RA, Gruber B, Tickle SP, Baker TS, Docherty AJ.

J Rheumatol. 1994 Dec;21(12):2329-33.

PMID:
7699637
3.

Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment.

Zucker S, Lysik RM, Zarrabi HM, Moll U, Tickle SP, Stetler-Stevenson W, Baker TS, Docherty AJ.

Ann N Y Acad Sci. 1994 Sep 6;732:248-62. Review. No abstract available.

PMID:
7978797
4.

Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays.

Zucker S, Mancuso P, DiMassimo B, Lysik RM, Conner C, Wu CL.

Clin Exp Metastasis. 1994 Jan;12(1):13-23.

PMID:
8287615
5.

Purification and characterization of a novel cytotoxic protein from transformed fibroblasts.

Zucker S, DiMassimo BI, Lysik RM, Lyubsky S.

Cancer Res. 1993 Mar 1;53(5):1195-203.

6.

M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.

Zucker S, Lysik RM, Zarrabi MH, Moll U.

Cancer Res. 1993 Jan 1;53(1):140-6.

7.

Human pleural effusions are rich in matrix metalloproteinases.

Hurewitz AN, Zucker S, Mancuso P, Wu CL, Dimassimo B, Lysik RM, Moutsiakis D.

Chest. 1992 Dec;102(6):1808-14.

PMID:
1446493
8.
9.

Type IV collagenase/gelatinase (MMP-2) is not increased in plasma of patients with cancer.

Zucker S, Lysik RM, Zarrabi MH, Stetler-Stevenson W, Liotta LA, Birkedal-Hansen H, Mann W, Furie M.

Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):475-9.

10.

Immunoassay of type IV collagenase/gelatinase (MMP-2) in human plasma.

Zucker S, Lysik RM, Gurfinkel M, Zarrabi MH, Stetler-Stevenson W, Liotta LA, Birkedal-Hansen H, Mann W.

J Immunol Methods. 1992 Apr 8;148(1-2):189-98.

PMID:
1373424
11.

Extraction of type IV collagenase/gelatinase from plasma membranes of human pancreatic cancer cells.

Zucker S, Moll UM, Lysik RM, DiMassimo EI, Schwedes JW, Liotta LA.

Matrix Suppl. 1992;1:411. No abstract available.

PMID:
1480078
12.

Proteinase-alpha 2 macroglobulin complexes are not increased in plasma of patients with cancer.

Zucker S, Lysik RM, Zarrabi MH, Fiore JJ, Strickland DK.

Int J Cancer. 1991 May 30;48(3):399-403.

PMID:
1710207
13.

Detergent extraction and characterization of tumor hemolytic factor from plasma membranes of oncogene transformed fibroblasts.

Zucker S, DiMassimo BI, Lysik RM, Vuaridel-Bonanomi E.

Int J Cancer. 1991 Jan 21;47(2):274-80.

PMID:
1988370
14.

Purification and characterisation of soluble tumour haemolytic factor isolated from oncogene transformed fibroblasts.

Zucker S, Wieman J, Lysik RM, Imhof B, Farooqui AA.

Br J Cancer. 1990 Jul;62(1):28-32.

15.

Extraction of type-IV collagenase/gelatinase from plasma membranes of human cancer cells.

Zucker S, Moll UM, Lysik RM, DiMassimo EI, Stetler-Stevenson WG, Liotta LA, Schwedes JW.

Int J Cancer. 1990 Jun 15;45(6):1137-42.

PMID:
2161801
16.

Chlorpromazine-induced immunopathy: progressive increase in serum IgM.

Zucker S, Zarrabi HM, Schubach WH, Varma A, Derman R, Lysik RM, Habicht G, Seitz PM.

Medicine (Baltimore). 1990 Mar;69(2):92-100.

PMID:
2319941
17.

Gelatin-degrading type IV collagenase isolated from human small cell lung cancer.

Zucker S, Wieman J, Lysik RM, Imhof B, Nagase H, Ramamurthy N, Liotta LA, Golub LM.

Invasion Metastasis. 1989;9(3):167-81.

PMID:
2542176
18.

Purification of a gelatin-degrading type IV collagenase secreted by ras oncogene-transformed fibroblasts.

Spinucci C, Zucker S, Wieman JM, Lysik RM, Imhof B, Ramamurthy N, Liotta LA, Nagase H.

J Natl Cancer Inst. 1988 Nov 2;80(17):1416-20.

PMID:
2845110
19.

Characterization of a connective tissue degrading metalloproteinase from human small cell lung cancer cells.

Zucker S, Turpeeniemi-Hujanen T, Wieman JM, Lysik RM.

Clin Exp Metastasis. 1988 Sep-Oct;6(5):363-75.

PMID:
2837354
20.

Metastatic mouse melanoma cells release collagen-gelatin degrading metalloproteinases as components of shed membrane vesicles.

Zucker S, Wieman JM, Lysik RM, Wilkie DP, Ramamurthy N, Lane B.

Biochim Biophys Acta. 1987 Apr 16;924(1):225-37.

PMID:
3030444
21.

Enrichment of collagen and gelatin degrading activities in the plasma membranes of human cancer cells.

Zucker S, Wieman JM, Lysik RM, Wilkie D, Ramamurthy NS, Golub LM, Lane B.

Cancer Res. 1987 Mar 15;47(6):1608-14.

22.

A role for interleukin-1 in the pathogenesis of Lyme disease.

Beck G, Habicht GS, Benach JL, Coleman JL, Lysik RM, O'Brien RF.

Zentralbl Bakteriol Mikrobiol Hyg A. 1986 Dec;263(1-2):133-6.

PMID:
3495083
23.

Purification of a hemolytic factor from ras oncogene transformed fibroblasts.

Wieman J, Zucker S, Wilkie D, Lysik RM.

Biochem Biophys Res Commun. 1986 Oct 15;140(1):365-71.

PMID:
3535788
24.

Diversity of human pancreatic cancer cell proteinases: role of cell membrane metalloproteinases in collagenolysis and cytolysis.

Zucker S, Lysik RM, Wieman J, Wilkie DP, Lane B.

Cancer Res. 1985 Dec;45(12 Pt 1):6168-78.

25.

Diversity of melanoma plasma membrane proteinases: inhibition of collagenolytic and cytolytic activities by minocycline.

Zucker S, Lysik RM, Ramamurthy NS, Golub LM, Wieman JM, Wilkie DP.

J Natl Cancer Inst. 1985 Sep;75(3):517-25.

PMID:
2993728
26.

Role for different cell proteinases in cancer invasion and cytolysis.

Zucker S, Beck G, DiStefano JF, Lysik RM.

Br J Cancer. 1985 Aug;52(2):223-32.

27.

Rat hematopoietic cell receptors for very low density lipoprotein (VLDL) growth inhibitor.

Zucker S, Beck G, Yi P, Lysik RM, DiStefano JF.

Exp Hematol. 1981 May;9(5):550-62.

PMID:
7238661
28.

Cancer cell inhibition of erythropoiesis.

Zucker S, Lysik RM, DiStefano JF.

J Lab Clin Med. 1980 Nov;96(5):770-82.

PMID:
7419961
29.

Very low density lipoprotein hematopoiesis inhibitor from rat plasma.

Zucker S, Lysik RM, Chikkappa G, Glucksman MJ, Gomez-Reino J, DiStefano JF.

Exp Hematol. 1980 Aug;8(7):895-905.

PMID:
16398021
30.

Liproprotein inhibitor of bone marrow cells in tumor-bearing rats.

Zucker S, Michael MS, Lysik RM, Glucksman MJ, Reese J, Rudin A, DiStefano J.

Cell Tissue Kinet. 1979 Jul;12(4):393-404.

PMID:
225031
31.

Bone marrow cytolysis induced by hepatoma, teratocarcinoma, and transformed fibroblasts.

Lysik RM, Cornetta K, DiStefano JF, Zucker S.

Cancer Res. 1979 Jan;39(1):30-4. No abstract available.

32.

Pathogenesis of anemia in rats with Walker 256 carcinosarcoma.

Zucker S, Lysik RM, Di Stefano J.

J Lab Clin Med. 1977 Sep;90(3):502-11.

PMID:
894104
33.

Erythropoiesis in chronic renal disease.

Zucker S, Lysik RM, Mohammad G.

J Lab Clin Med. 1976 Oct;88(4):528-35.

PMID:
965807
34.

Diminished bone marrow responsiveness to erythropoietin in myelophthisic anemia.

Zucker S, Lysik RM, Friedman S.

Cancer. 1976 Mar;37(3):1308-15.

PMID:
1260653
35.

Bone marrow erythropoiesis in the anemia of infection, inflammation, and malignancy.

Zucker S, Friedman S, Lysik RM.

J Clin Invest. 1974 Apr;53(4):1132-8.

Supplemental Content

Loading ...
Support Center